INS and Hypoglycemia: This increase in hypoglycemia risk is higher than previously described,23,24,25,32 but those studies did not directly compare sulfonylurea, basal insulin, multiple daily insulin injections, and other glucose level–lowering drugs with each other and within the same diverse patient population in a real-world setting.